Cost-effectiveness analysis finds semaglutide cost-effective for obesity and heart disease without diabetes, highlighting its economic value under standard willingness-to-pay thresholds.
Semaglutide 2.4 mg use as in SELECT is cost-effective at list price, using a $150,000/QALY willingness-to-pay threshold.
No takes yet. Share an insight, caveat, or question.
McEwan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: